Heyman Richard A.
SEC CIK 1584759 · EDGAR
BoughtSold
Most active insiders at ORIC, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Piscitelli Dominic | CFO | — | $2.01M |
| 2 | Chacko Jacob | Pres AND CEO, Dir | — | $1.82M |
| 3 | Heyman Richard A. | Dir | — | $241.5K |
| 4 | Multani Pratik S | Chief Medical Off | — | $97.1K |
| 5 | Kunkel Lori Anne | Dir | — | — |
Transactions 36
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-28 16:15 | 2026-07-24 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | M - OptEx | $1.60 | +3,500 | 45.3K | +8% | +$5,600 |
| DT | 2026-07-28 16:15 | 2026-07-24 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale+OE | $12.02 | -7,000 | 38.3K | -15% | -$84.1K |
| DTI | 2026-07-28 16:15 | 2026-07-24 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale+OE | $12.02 | -6,100 | 206.7K | -3% | -$73.3K |
| TI | 2026-07-08 16:35 | 2026-07-06 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $12.00 | -300 | 212.8K | -0.1% | -$3,600 |
| I | 2026-02-19 | 2026-02-17 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $26.18 | -1,230 | 22.6K | -5% | -$32.2K |
| MI | 2026-01-22 | 2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $26.75 | -1,230 | 23.9K | -5% | -$32.9K |
| I | 2026-01-20 | 2026-01-16 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $12.00 | -3,200 | 213.1K | -1% | -$38.4K |
| 2026-01-20 | 2026-01-16 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $12.00 | -3,500 | 41.8K | -8% | -$42.0K | |
| MI | 2026-01-12 | 2026-01-08+ | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $25.02 | -13.9K | 25.5K | -35% | -$348.3K |
| DM | 2025-10-03 | 2025-10-03 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | M - OptEx | $1.69 | +32.8K | 45.3K | +262% | +$55.6K |
| I | 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $30.00 | -753 | 27.2K | -3% | -$22.6K |
| 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $30.00 | -817 | 123.7K | -0.7% | -$24.5K | |
| 2024-10-17 | 2024-10-15 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $27.67 | -1,270 | 124.5K | -1% | -$35.1K | |
| 2024-10-08 | 2024-10-04 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $27.51 | -2,825 | 125.8K | -2% | -$77.7K | |
| 2024-10-03 | 2024-10-01 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $27.54 | -518 | 128.6K | -0.4% | -$14.3K | |
| 2024-09-18 | 2024-09-16 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $22.41 | -1,270 | 129.1K | -1.0% | -$28.5K | |
| M | 2024-08-19 | 2024-08-15 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $23.25 | -1,270 | 130.4K | -1.0% | -$29.5K |
| I | 2024-08-02 | 2024-07-31 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $27.50 | -649 | 27.9K | -2% | -$17.8K |
| 2024-08-02 | 2024-07-31 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $27.51 | -1,702 | 131.6K | -1% | -$46.8K | |
| 2024-07-17 | 2024-07-15 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $24.80 | -1,270 | 133.3K | -0.9% | -$31.5K | |
| 2024-06-20 | 2024-06-17 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $21.48 | -1,270 | 134.6K | -0.9% | -$27.3K | |
| 2024-05-20 | 2024-05-16 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $23.74 | -1,270 | 135.9K | -0.9% | -$30.1K | |
| M | 2024-04-15 | 2024-04-11+ | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $24.02 | -6,315 | 137.2K | -4% | -$151.7K |
| I | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $25.00 | -649 | 28.6K | -2% | -$16.2K |
| 2024-03-21 | 2024-03-19 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $14.50 | -1,270 | 143.5K | -0.9% | -$18.4K | |
| 2024-02-20 | 2024-02-15 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $17.42 | -1,270 | 144.7K | -0.9% | -$22.1K | |
| 2024-02-01 | 2024-01-30 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $16.41 | -1,270 | 146.0K | -0.9% | -$20.8K | |
| M | 2023-12-26 | 2023-12-21+ | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $13.00 | -175 | 147.4K | -0.1% | -$2,275 |
| MI | 2023-12-26 | 2023-12-21+ | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $13.00 | -41 | 29.3K | -0.1% | -$533 |
| M | 2023-12-21 | 2023-12-19+ | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $13.02 | -2,365 | 147.5K | -2% | -$30.8K |
| I | 2023-12-21 | 2023-12-20 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $13.02 | -1,915 | 29.3K | -6% | -$24.9K |
| D | 2023-02-27 | 2023-02-23 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | A - Grant | — | +149.8K | 149.8K | New | — |
| DMI | 2023-02-27 | 2023-02-23 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | A - Grant | — | +68.6K | 31.2K | New | — |
| MI | 2021-09-16 | 2021-09-14+ | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $25.04 | -1,388 | 217.0K | -0.6% | -$34.8K |
| MI | 2021-09-14 | 2021-09-10+ | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $25.05 | -1,080 | 218.3K | -0.5% | -$27.1K |
| I | 2021-09-09 | 2021-09-07 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $25.11 | -1,086 | 218.7K | -0.5% | -$27.3K |
Purchase Sale Sale after option exercise All abbreviations